SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/7F935053E3B1E1B15CB7E1CF0B90F9CF06086D2D4C4499B08329A6B4EB4F35D96161DC4AFA3F9068E0B5D3E86A2A1DB2>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/7F935053E3B1E1B15CB7E1CF0B90F9CF06086D2D4C4499B08329A6B4EB4F35D96161DC4AFA3F9068E0B5D3E86A2A1DB2
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/7F935053E3B1E1B15CB7E1CF0B90F9CF06086D2D4C4499B08329A6B4EB4F35D96161DC4AFA3F9068E0B5D3E86A2A1DB2
http://www.w3.org/2000/01/rdf-schema#comment
"The presence of CYP2C9*2 and/or *3 genotypes is associated with unstable warfarin treatment in patients after heart valve replacement regardless of the type of INR testing."
xsd:string
http://purl.uniprot.org/uniprot/#_45C2BCACA34A31D42B15781448AC75FF178E902F01CB2D6ABF3A219F6C1C20F759B00F0A174C1B5158B6435F58FFB05A
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/7F935053E3B1E1B15CB7E1CF0B90F9CF06086D2D4C4499B08329A6B4EB4F35D96161DC4AFA3F9068E0B5D3E86A2A1DB2
http://purl.uniprot.org/uniprot/S5RV20
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/7F935053E3B1E1B15CB7E1CF0B90F9CF06086D2D4C4499B08329A6B4EB4F35D96161DC4AFA3F9068E0B5D3E86A2A1DB2
http://purl.uniprot.org/uniprot/#_S5RV20-mappedCitation-26469104
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/7F935053E3B1E1B15CB7E1CF0B90F9CF06086D2D4C4499B08329A6B4EB4F35D96161DC4AFA3F9068E0B5D3E86A2A1DB2